Interpreting 7-Year Valve Durability in PARTNER 3—Reply - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reply: Interpreting Seven-Year Valve Durability Findings From PARTNER 3

  • By

  • Philippe Pibarot

  • Julien Ternacle

  • Rebecca Hahn

  • November 1, 2026

Share

Objective:

Respond to concerns about how valve choice and durability measures affect interpretation of seven-year PARTNER 3 results.

Approach:
  • Valve selection: Surgeons selected surgical bioprostheses they considered appropriate during trial enrollment, when Trifecta valves were regarded as an option without known late failure concerns.
  • Sensitivity analyses: The authors excluded Trifecta and Mitroflow valves to assess whether these devices affected comparisons of valve failure.
  • Durability measures: The reply contrasts reintervention with all-cause bioprosthetic valve failure (BVF), which includes reintervention, valve-related death, and irreversible severe valve dysfunction.
Key Findings:
  • After excluding Trifecta and Mitroflow valves, all-cause BVF rates were 6.9% with TAVR and 5.4% with surgery (P = .42).
  • BVF attributed to structural valve deterioration was 3.9% with TAVR and 3.4% with surgery (P = .69).
  • No PARTNER 3 participants were younger than 50 years, and 9.5% were aged 50 to 65 years; the authors therefore describe mechanical valve replacement as largely infeasible in this trial.
  • The authors state that newer balloon-expandable valves using Resilia tissue might have different durability outcomes, but characterize this possibility as hypothetical.
Interpretation:

The authors argue that reintervention alone may underestimate valve failure when clinical or patient-specific circumstances delay or prevent another procedure. They also state that durability may vary among valve platforms and that comparisons should reflect the range of platforms used in practice.

Limitations:
  • The proposed durability advantage of Resilia tissue is hypothetical in this reply.
  • The reply notes that PARTNER 3 included few patients aged 50 to 65 years and none younger than 50 years, limiting the relevance of mechanical-valve options to its population.
Sources:

Original Source(s)

Related Content